Back to search

Article

Safety and exceptional immunogenicity of novel 5T4 viral vectored vaccination regimes in early stage prostate cancer: a phase I clinical trial

2020-03-06

Abstract excerpt

Prostate cancer (PCa) has been under investigation as a target for antigen-specific immunotherapies in metastatic disease settings for a decade. However, neither of the two clinically most developed prostate cancer vaccines, Sipuleucel-T and ProstVac, induce strong T cell immunity. In this first-in-man study, VANCE, we evaluated a novel vaccination platform based on two replication-deficient viruses, chimpanzee ad...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5b819362-7446-5bd2-925b-4aaa02a3542d
DOI
10.1101/2020.03.05.20031500
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety and exceptional immunogenicity of novel 5T4 viral vectored vaccination regimes in early stage prostate cancer: a phase I clinical trialDOI 10.1101/2020.03.05.20031500
DNA vaccines for the treatment of prostate cancerSemantic proximity
PSMA-CAR-T Cells for Metastatic Castration-Resistant Prostate Cancer: An Integrated Framework for Translational OptimizationSemantic proximity
The viral vectored vaccine targeting Thymosin β10 controls tumour growth in a murine model of prostate cancerSemantic proximity
The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeuticSemantic proximity
T cell transcriptional and receptor signatures predict response to telomerase vaccination in prostate cancerSemantic proximity
Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate CancerSemantic proximity
DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles.Semantic proximity
Targeting of a STING Agonist to Perivascular Macrophages in Prostate Tumors Delays Resistance to Androgen Deprivation TherapySemantic proximity
Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored VaccineSemantic proximity
Development of novel vaccine vectors: Chimpanzee adenoviral vectorsSemantic proximity
Prostate Stem Cell Antigen DNA Vaccination Breaks Tolerance to Self-antigen and Inhibits Prostate Cancer GrowthSemantic proximity
Safety and Immunogenicity of Adenovirus-Vectored Near-Consensus HIV Type 1 Clade B <i>gag</i> Vaccines in Healthy AdultsSemantic proximity
Select a neighboring publication to make it the new centre.